Apixaban Prophylaxis Dosing
The prophylactic dose of apixaban is 2.5 mg orally twice daily for most indications requiring VTE prophylaxis. 1
Clinical Context-Specific Dosing
Post-Surgical Orthopedic Prophylaxis
- Dose: 2.5 mg orally twice daily 1
- Timing: Initial dose 12-24 hours after surgery 1
- Duration:
- This regimen was validated in the ADVANCE trials, demonstrating superiority to enoxaparin for VTE prevention 2
Cancer-Associated VTE Prophylaxis (Outpatient)
- Dose: 2.5 mg orally twice daily 3
- Duration: Typically up to 6 months, though optimal duration remains uncertain 3
- This dose is recommended for ambulatory cancer patients at high risk for VTE 3
- Important caveat: Extended prophylaxis beyond initial treatment may be considered after initial LMWH or UFH administration 4
Extended Secondary VTE Prophylaxis (After Completing Initial Treatment)
- Dose: 2.5 mg orally twice daily 1, 5
- Indication: For patients who have completed at least 6 months of anticoagulation for DVT or PE 1
- The AMPLIFY-EXT trial demonstrated that this reduced dose significantly reduced recurrent VTE (1.7% vs 8.8% with placebo) without increasing major bleeding (0.2% vs 0.5%) 5
- Recent evidence in cancer patients shows this dose is effective and safe for extended prophylaxis, with VTE recurrence rates of 7.6% over 30 months 6
- The API-CAT trial confirmed that 2.5 mg twice daily was noninferior to 5 mg twice daily for preventing recurrent VTE in cancer patients (2.1% vs 2.8%), with significantly less bleeding (12.1% vs 15.6%) 7
Medical Patients (Hospitalized)
- Note: Apixaban 2.5 mg twice daily was studied in the ADOPT trial for acutely ill medical patients but was not superior to standard enoxaparin prophylaxis and showed increased bleeding risk 2
- Therefore, apixaban is not routinely recommended for medical thromboprophylaxis in hospitalized patients 2
Key Dosing Distinctions
Critical differentiation: The prophylactic dose (2.5 mg twice daily) differs substantially from treatment doses:
- Treatment dose for acute VTE: 10 mg twice daily for 7 days, then 5 mg twice daily 1
- Prophylactic dose: 2.5 mg twice daily 1
Renal Considerations for Prophylaxis
- Apixaban 2.5 mg twice daily can be used with creatinine clearance >25 mL/min 8, 1
- For severe renal impairment (CrCl <15 mL/min), no specific recommendation exists 9, 8
- The FDA label indicates apixaban should be avoided in patients with CrCl <15 mL/min or on dialysis for most indications, though some data support use in dialysis patients for atrial fibrillation 9, 8
Drug Interactions Affecting Prophylactic Dosing
- Avoid combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) when using the 2.5 mg twice daily dose 1
- If such inhibitors are necessary, alternative anticoagulation should be considered 1
Common Pitfalls
- Do not confuse prophylactic dosing (2.5 mg twice daily) with atrial fibrillation dosing (5 mg twice daily, or 2.5 mg twice daily only if ≥2 dose-reduction criteria present) 1
- Do not use apixaban for routine medical thromboprophylaxis in hospitalized patients—LMWH or UFH remain preferred 3, 2
- Ensure proper timing post-operatively: 12-24 hours after surgery, not immediately 1